Audited Financial Results for the quarter and year ended March 31, 2026
RESULTS
▼ Concern Flagged
HIGH RISK
📅 Filed on BSE: 03 Jun 2026, 09:37 PM IST · BSE ID: 3bda2e7f-0581-4d16-9f90-61181f5f584d
View Original BSE Filing (PDF)
💡
In Simple Terms
Dr Lalchandani Labs reported a loss of 13.15 Lacs for the last six months of the financial year.
🤖 AI Summary
- Board approved audited standalone financial results for the year ended March 31, 2026.
- Profit/(Loss) for the half year ended March 31, 2026, was (13.15) INR Lacs.
- Revenue from operations for the year ended March 31, 2026, totaled 441.80 INR Lacs.
- Basic Earnings Per Share (EPS) for the half year ended March 31, 2026, was (0.15) Rs.
- M/s. Brickwork Ratings India Private Limited appointed Monitoring Agency for Rights Issue proceeds.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Yearly Ended Mar 31, 2026)
441.80 INR Lacs
Revenue from operations (Yearly Ended Mar 31, 2025)
464.03 INR Lacs
Profit/(Loss) for the period (Half Year Ended Mar 31, 2026)
(13.15) INR Lacs
Basic EPS (Half Year Ended Mar 31, 2026)
(0.15) Rs.
Total Expenses (Yearly Ended Mar 31, 2026)
470.05 INR Lacs
Waived loan amount (Exceptional gain)
61.08 lacs
🏢 How This Affects the Company
The company reported a Profit/(Loss) for the half year ended March 31, 2026, of (13.15) INR Lacs. Revenue from operations for the year decreased to 441.80 INR Lacs in FY26 from 464.03 INR Lacs in FY25.
The appointment of M/s. Brickwork Ratings India Private Limited as Monitoring Agency affects compliance procedures related to Rights Issue proceeds utilization.
The auditor's report highlights multiple qualified opinions including non-compliance with NPA accounting, one-time settlement gain of Rs. 61.08 lacs in exceptional gains, and failure to pay statutory dues like PF, ESI, and TDS, indicating increased financial and regulatory compliance risk.
👥 What This Means For Shareholders
✅
Action Required
No direct action is required from shareholders based on this filing.
👤
Who Is Affected
Shareholders are affected by the company's reported half-year loss of (13.15) INR Lacs and the qualified audit opinions which highlight financial and compliance issues.
🔍
Management Signal
Management's decision to approve results despite auditor qualifications indicates a focus on formal compliance with reporting timelines while outstanding issues are addressed.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 results — monitor for improvements in revenue and profitability.
Auditor's next report — check resolution of qualified opinions regarding statutory dues.
Monitoring Agency reports — review utilization of Rights Issue proceeds.
HIGH RISK
Multiple qualified audit opinions on financial statements and non-payment of statutory dues indicate significant operational and financial risks.
💡 Investor Takeaway
Dr Lalchandani Labs Ltd. reported a Profit/(Loss) of (13.15) INR Lacs for the half year ended March 31, 2026, with annual revenue at 441.80 INR Lacs. Auditors issued qualified opinions on NPA accounting, one-time settlement gain of Rs. 61.08 lacs, unpaid statutory dues, and unprovided doubtful debts.
⚖️ Strengths & Concerns
⚠️ Concerns
- Profit/(Loss) for the half year ended March 31, 2026, was (13.15) INR Lacs.
- Annual revenue from operations for FY26 decreased to 441.80 INR Lacs from 464.03 INR Lacs in FY25.
📅 Company Track Record
Dr Lalchandani Labs previously reported a half-year loss of (13.15) INR Lacs for March 2026. This filing confirms the audited results and provides annual figures, showing a slight decrease in annual revenue from 464.03 INR Lacs in FY25 to 441.80 INR Lacs in FY26.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What were Dr Lalchandani Labs Ltd.'s audited financial results for the year ended March 31, 2026?
Dr Lalchandani Labs Ltd.'s audited revenue from operations for the year ended March 31, 2026, was 441.80 INR Lacs, with a Profit/(Loss) for the period of 6.35 INR Lacs.
What was Dr Lalchandani Labs Ltd.'s profit or loss for the half year ended March 31, 2026?
Dr Lalchandani Labs Ltd. reported a Profit/(Loss) of (13.15) INR Lacs for the half year ended March 31, 2026.
What was the Basic Earnings Per Share (EPS) for Dr Lalchandani Labs Ltd. for the half year ended March 31, 2026?
The Basic Earnings Per Share (EPS) for Dr Lalchandani Labs Ltd. for the half year ended March 31, 2026, was (0.15) Rs.
Which agency was appointed as Monitoring Agency for Dr Lalchandani Labs Ltd.'s Rights Issue proceeds?
M/s. Brickwork Ratings India Private Limited was appointed as Monitoring Agency for the utilization of Rights Issue Proceeds for the quarters ended March 31, 2026, and June 30, 2026.
What was the total amount of waived loan reported by Dr Lalchandani Labs Ltd.?
Dr Lalchandani Labs Ltd. reported a waived loan amount of Rs. 61.08 lacs as part of an One Time Settlement (OTS scheme) for unsecured loans.
Questions based on this BSE filing only. For information purposes.